Revolution Medicines
700 Saginaw Drive
Redwood City
California
94063
United States
Tel: (650) 481-6801
Website: http://www.revolutionmedicines.com/
About Revolution Medicines
REVOLUTION Medicines discovers and develops important new medicines for cancer patients by translating frontier oncology targets – proteins that drive the growth of cancers or that control immune responses that can defeat them. The company has a robust pipeline of R&D programs focused on frontier targets, including SHP2 (PTPN11), a tyrosine phosphatase enzyme that regulates cancer growth signaling and the immune response, SHP1 (PTPN6), a second tyrosine phosphatase that regulates multiple arms of the immune response, and 4EBP1, a key regulator of oncogene translation in the PI3K/AKT/mTOR pathway.
Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investors through $126 million raised in Preferred Series A & B rounds.
14 articles with Revolution Medicines
-
Ginkgo Bioworks Acquires Warp Drive Bio's Genome Mining Platform for Discovery and Development of Novel Classes of Antibiotics
5/15/2019
Acquisition expands Ginkgo's biological codebase for organism engineering for the production of natural product pharmaceuticals
-
REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019
1/4/2019
REVOLUTION Medicines, Inc., a biotechnology company that translates frontier oncology targets to outsmart cancer, today announced that it will make a presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
-
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
10/16/2018
REVOLUTION Medicines, Inc. and Warp Drive Bio, Inc. announced today that REVOLUTION Medicines is acquiring Warp Drive Bio.
-
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
10/9/2018
Scientific publication reports preclinical results showing precision oncology opportunity for targeting SHP2 in genetically selected tumors
-
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
7/18/2018
Preclinical studies of SHP2 inhibitors demonstrated promise across multiple forms of cancer; lead drug candidate expected to start clinical trials in second half of 2018.
-
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
-
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...
4/24/2018
Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors. -
REVOLUTION Medicines Raises $56 Million Series B Financing
4/24/2018
REVOLUTION Medicines, Inc. announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities.
-
Revolution Medicines Appoints Vincent Miller, M.D. To Board Of Directors
10/6/2017
-
Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey As President Of Research And Development
3/20/2017
-
Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million
12/21/2016
-
Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., And Senior Advisor, Eric Gordon, Ph.D.
6/14/2016
-
Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of Revolution Medicines
6/1/2015
-
Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors
4/9/2015